Date Filed | Type | Description |
10/11/2023 |
8-K
| Quarterly results |
10/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/03/2023 |
8-K
| Quarterly results |
07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
06/02/2023 |
8-K
| Appointed a new director |
06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
03/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/01/2023 |
SC 13G
| Glenview Capital reports a 5.3% stake in Myriad Genetics, Inc. |
03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/28/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 11.5% stake in Myriad Genetics Inc. |
02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/31/2023 |
SC 13G/A
| STATE STREET CORP reports a 6.2% stake in AMENDED FILING MYRIAD GENETICS INC |
01/09/2023 |
SC 13G/A
| EARNEST PARTNERS LLC reports a 4.1% stake in MYRIAD GENETICS, INC. |
11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/01/2022 |
8-K
| Quarterly results |
08/05/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/04/2022 |
8-K
| Quarterly results |
07/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
06/29/2022 |
8-K
| Quarterly results |
06/06/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/02/2022 |
8-K
| Quarterly results |
05/12/2022 |
SC 13G
| Camber Capital Management LP reports a 5.8% stake in Myriad Genetics, Inc. |
05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/05/2022 |
8-K
| Quarterly results |
04/14/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/14/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/01/2022 |
8-K
| Other Events Interactive Data |
02/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|